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The effect of the antiepileptic drug valproic acid (VPA) on mitochondrial oxidative phosphorylation (OXPHOS) was investigated in vitro. Two
experimental approaches were used, in the presence of selected respiratory-chain substrates: (1) formation of ATP in digitonin permeabilized rat
hepatocytes and (2) measurement of the rate of oxygen consumption by polarography in rat liver mitochondria. VPA (0.1–1.0 mM) was found to
inhibit oxygen consumption and ATP synthesis under state 3 conditions with glutamate and 2-oxoglutarate as respiratory substrates. No inhibitory
effect on OXPHOS was observed when succinate (plus rotenone) was used as substrate. We tested the hypothesis that dihydrolipoyl
dehydrogenase (DLDH) might be a direct target of VPA, especially its acyl-CoA intermediates. Valproyl-CoA (0.5–1.0 mM) and valproyl-
dephosphoCoA (0.5–1.0 mM) both inhibited the DLDH activity, acting apparently by different mechanisms. The decreased activity of DLDH
induced by VPA metabolites may, at least in part, account for the impaired rate of oxygen consumption and ATP synthesis in mitochondria if 2-
oxoglutarate or glutamate were used as respiratory substrates, thus limiting the flux of these substrates through the citric acid cycle.
© 2007 Elsevier B.V. All rights reserved.Keywords: Valproic acid; Oxidative phosphorylation; Dihydrolipoyl dehydrogenase; Valproyl-CoA; Mitochondrial dysfunction; Drug-induced hepatotoxicityThe association between valproic acid, an effective anticon-
vulsant drug, with hepatotoxicity and steatosis is well
documented [1–3]. After acetaminophen and trogliatzone,
valproate drug has been referred as the third most common
xenobiotic suspected of causing death due to liver injury [4].Abbreviations: VPA, 2-n-propylpentanoic acid or valproic acid; Δ2(E)-VPA,
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doi:10.1016/j.bbabio.2007.06.007Besides the inhibition of mitochondrial fatty acid β-oxidation,
the impairment of oxidative phosphorylation (OXPHOS) is an
important mechanism leading to mitochondrial dysfunction,
which plays a central role in valproate-induced steatosis and
steatohepatitis [5,6]. OXPHOS is regulated by a complex variety
of factors and any xenobiotic that may inhibit this pathway will
compromise normal mitochondrial function. However, the
mechanisms involved in the drug-induced effects on OXPHOS
are still far from being resolved.
Valproic acid (VPA) and its metabolites have been reported
to inhibit mitochondrial OXPHOS as first described by Haas et
al. who demonstrated a direct effect of VPA on mitochondrial
substrate oxidation in vitro [7–9]. This effect was also studied
following the in vivo administration of VPA [10–12]. The
reported data are, however, quite variable, depending on the
approach, on the type of substrate used and on the degree of
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effects of VPA on mitochondrial OXPHOS were re-evaluated in
an attempt to further explain one of our previous findings [13]
of a striking effect of the drug on mitochondrial pyruvate
oxidation. The effects of VPA and of two unsaturated meta-
bolites, Δ2(E)-VPA and Δ4-VPA, were studied on the energy
metabolism driven by two substrates, glutamate and 2-oxoglu-
tarate. Furthermore, we studied the hypothesis whether the
obtained effects were due to a specific inhibition at the level of
dihydrolipoamide dehydrogenase (DLDH), the common com-
ponent (E3) of the multi-enzyme complexes 2-oxoglutarate
dehydrogenase, pyruvate dehydrogenase and the branched-
chain 2-oxoacid dehydrogenase [14]. The measurement of the
activity of this individual enzyme was performed in the
presence of two potential inhibitors: valproyl-CoA and
valproyl-dephosphoCoA (dephCoA). The former is the acyl-
CoA ester of VPA that is formed in higher concentration in the
mitochondrial matrix [15] and the strongest inhibitor of the
glycine cleavage system (GCS) as compared with VPA [16,17].
The second VPA metabolite was identified by our group [18] as
being a potential dephosphorylation product of the adenosine
moiety of valproyl-CoA.
1. Materials and methods
Reagents and chemicals: VPA was obtained from Sigma Chemical Co.
(St. Louis, MO, USA) as well as D,L-lipoamide, bovine serum albumin (fatty
acid free) (BSA), bicinchoninic acid (BCA) and other biochemical standards.
Δ2(E)-VPA and Δ4-VPA were a kind gift of Prof. Dr. D. Lindhout (University
Medical Center, Utrecht). Valproyl-CoA and valproyl-dephosphoCoA were
synthesised as described previously [15,18]. 2-Oxoglutarate dehydrogenase
(2-OGDH) (from porcine heart) was obtained from Sigma Chemical Co (St.
Louis, MO, USA). ADP, ATP, NAD and NADH were obtained from
Boehringer Mannheim GmbH (Germany).
1.1. Preparation of hepatocytes and rat liver mitochondria
Male Wistar rats (200–250 g) were given a standard laboratory diet.
Hepatocytes were isolated according to established procedures essentially
using the method of Berry and Friend [19] and subsequently suspended in
Krebs Henselheit buffer (pH=7.4). Cell viability was routinely tested by
trypan blue (0.4% w/v) exclusion and phase contrast microscopy. Preparations
with more than 10% damaged cells were discarded. Protein was determined by
the bicinchoninic acid (BCA) assay [20] using bovine serum albumin as a
reference substance. Cell viability was tested in parallel incubations. The
inclusion of VPA, Δ2(E)-VPA or Δ4-VPA did not induce a decrease in cell
viability compared with the control conditions, within the used incubation
time at 37 °C.
Adult male Wistar rats (about 250 g) were starved for 18 h and used for
preparation of mitochondria. After decapitation, the livers were rapidly
removed and rinsed into ice-cold homogenization medium (250 mM manitol,
5 mM Tris–HCl, 0.5 mM EGTA; pH=7.4). Rat liver mitochondria were
prepared according to a published procedure [15]. The mitochondria were
finally resuspended in the homogenization medium (25–50 mg/mL).
Mitochondrial protein content was measured using the BCA assay and BSA
as a reference substance. All incubations with VPA and its metabolites were
performed in freshly isolated mitochondria.
1.2. Synthesis of ATP using rat hepatocytes
Measurement of ATP synthesis in digitonin permeabilized hepatocytes was
essentially based on the method described by Wanders et al. [21]. The cells
were suspended in Krebs Henselheit buffer (pH=7.4). Hepatocytes (finalconc. 0.4 mg/mL) were pre-incubated for 10 min at 25° C, in the presence and
absence (controls) of VPA or its unsaturated metabolites, Δ2(E)-VPA and Δ4-
VPA. As the solution ofΔ2(E)-VPAwas prepared in DMSO, DMSO was added
to the control incubations at the same final concentration (1%). Reactions were
started by adding ADP (1 mmol/L) and allowed to proceed for 30 min at 25 °C
in a cytosol-mimicking medium containing 15 mg/mL digitonin (optimal
concentration previously established for hepatocytes; results not shown),
150 mM KCl, 25 mM Tris–HCl (pH=7.4), 2 mM EDTA, 10 mM potassium
phosphate buffer (pH=7.4), 0.1% bovine serum albumine and the respiratory
substrates: 10 mM succinate (plus 20 μg/mL rotenone), 10 mM L-glutamate
(plus or minus 5 mM L-malate) and 10 mM 2-oxoglutarate. VPAwas added to
the reaction medium from a stock solution at pH=7.4. For each respiratory
substrate, additional negative controls were tested in the presence of 50 mM
2,4-dinitrophenol (DNP). Reactions were stopped with 2 M perchloric acid
with vortexing. After 15 min on iced water, samples were centrifuged for 5
min at 10,000g (4 °C) and the supernatants neutralised to pH=6–7 with 2 M
KOH/ 0.6 M MOPS. The ATP produced was measured fluorimetrically in the
protein-free supernatants according to a standard procedure [22].
1.3. Respiration oxidation rates using rat liver mitochondria
The effect of VPA and Δ4-VPA on mitochondrial respiratory function was
assessed by means of a polarographic technique using intact rat liver
mitochondria in the presence of the following respiratory substrates: succinate
(plus rotenone), L-glutamate (plus or minus L-malate) and 2-oxoglutarate.
Oxygen consumption was measured at 25 °C in a Clark-type membrane
coated oxygen electrode (Hansatech, Instr.) in a 0.5 mL incubation reaction
vessel. The medium had the following composition: 250 mM mannitol, 5 mM
Tris–HCl, 0.5 mM EGTA, 10 mM potassium phosphate buffer (pH=7.4) and
0.5% BSA. Mitochondrial protein was used at a concentration of 0.4 mg/mL,
with 10 mM succinate (plus 3 μM rotenone) or 10 mM glutamate (plus or
minus 5 mM malate), and at 1.0 mg/mL when 10 mM 2-oxoglutarate was used
as substrate. VPA was added to the reaction medium from a stock solution at
pH=7.4. After an equilibration period in the presence of the respective
substrate and eventually the inhibitor (plus or minus VPA or Δ4-VPA), ADP
(0.2 mM) was added to initiate state 3 oxidation. Evaluation of states 3 and 4
and the subsequent calculation of the respiratory control indexes and P/O-
ratios were essentially done according to Estabrook [23], assuming an oxygen
concentration of 0.253 μmol/mL (O2) under the conditions described above.
1.4. Measurement of dihydrolipoamide dehydrogenase (E3 subunit)
activity using purified 2-OGDH
Dihydrolipoamide dehydrogenase activity was measured according to a
method adapted from Reed et al. [24]. Considering that the kinetics of the
reaction catalysed by DLDH in the forward direction (a) is technically very







LipðSÞ2 þ NADHþ þ Hþ
ðLipoamideÞ
The assay is based on the spectrophotometric determination of the rate of
NADH oxidation (at 340 nm) in the presence of the dehydrogenase and
lipoamide. The standard assay mixture contained 200 μM NADH in 150 mM
potassium phosphate buffer (pH=6.7), water and enzyme solution, making a
total volume of 500 μL. Reactions were initiated by adding 25 μL of 3 mM
lipoamide dissolved in 4.8% ethanol (solution made immediately before use) to
the mixture described above. The temperature was maintained at 37 °C. Stock
solution of the enzyme complex contained 0.28 U/mg for 2-OGDH. The
respective enzyme solution (2-OGDH) was prepared in phosphate buffered
saline (PBS) immediately before the assay to avoid loss of catalytic activity.
Valproyl-CoA and valproyl-dephosphoCoAwere added to the medium and
the decrease in absorbance was monitored for 5 min before starting the reaction.
The addition of the substrate lipoamide was therefore done after a pre-incubation
of 5 min at 37 °C. A complete inactivation of the enzyme was achieved using
arsenite (10 mM) which gave an enzyme activity less than 3% of the control,
measured under the same conditions but in the absence of the inhibitor.
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The parameters (Km and Vmax) of enzyme kinetics were obtained by
four methods of calculation: three linearizations of the Michaelis–Menten
equa t ion V ¼ ½S  Vmax= ½S þ Kmð ÞðLineweaver  Burk 1=V ¼ f 1=½Sð Þ;
Eadie Hofstee V ¼ f V=½Sð Þ; and Hanes-Woolf ½S=V ¼ f ½Sð ÞÞ and the
direct linear plot of Cornish Bowden Vmax ¼ f Kmð Þ [25].
The best-fit curves of the Michaelis–Menten equation to the experimental
data were obtained through non-linear regression analysis by the computer
software Berkeley Madonna (v. 8.0®, Macey and Oster).2. Results
2.1. Effect of VPA, Δ2(E)-VPA and Δ4-VPA on the rate of ATP
synthesis
In order to study the effect of VPA (0.1–2.0 mM) and its
unsaturated metabolites, Δ2(E)-VPA (1 mM) and Δ4-VPA
(1 mM), on ATP-synthesis in mitochondria, rat hepatocytes
were permeabilized with digitonin and incubated with different
substrates, including succinate (plus rotenone), L-glutamate (plus
L-malate), L-glutamate and 2-oxoglutarate under state 3 condi-
tions. The incubations made without the parent drug or its
metabolites were considered as controls and the obtained oxi-
dation rates were taken as 100%. The absolute values for
reference ranges of the rates of ATP synthesis, expressed in nmolFig. 1. Effect of VPA (variable concentration) (graphs A-I and B-I) and its unsaturated
on the: (A) ATP production rate, in rat hepatocytes, (B) oxygen consumption in rat li
rotenone) –■–, glutamate (plus malate) –●–, glutamate –▴–, and 2-oxoglutarate. –
a representative experiment; similar results were obtained in three other experimen
respective error bar. The estimated value for the standard deviation (%) for all pointATP/min/mg protein, were: 41.05–41.23, 48.02–49.82, 34.74–
35.50 and 18.59–18.90 respectively for succinate (plus rotenone),
L-glutamate (plus L-malate), L-glutamate and 2-oxoglutarate.
VPA was found to inhibit the rate of ATP synthesis in the
presence of glutamate and 2-oxoglutarate as respiratory
substrates, respectively (Fig. 1A–I). No inhibitory effect was
observed on succinate driven-oxidative phosphorylation and
only a very mild one (20–25%) with glutamate/malate as
substrate couple.
Fig. 1A-II shows that ATP synthesis was also selectively
inhibited by Δ4-VPA depending on the respiratory substrate
used. As observed with VPA, ATP synthesis remained
practically unaffected by Δ4-VPA with succinate/rotenone as
substrate, whereas ATP synthesis was clearly inhibited when 2-
oxoglutarate or L-glutamate was used as a respiratory substrate.
These results suggest that VPA andΔ4-VPA may have a similar
mechanism of inhibition most probably different from that of
Δ2(E)-VPA, which induced a much milder inhibitory effect on
ATP synthesis driven by the same substrates (70–90% of
control).
2.2. Effect of VPA and Δ4-VPA on the oxygen consumption rate
The effects of VPA and Δ4-VPA on the oxidation rate of
succinate (plus rotenone), glutamate (plus or minus malate),metabolites,Δ4-VPA andΔ2(E)-VPA (graphs A-II and B-II, all at conc.=1 mM),
ver mitochondria, both driven by different respiratory substrates: succinate (plus
▾– (see Materials and methods for experimental details; the data shown are from
ts; the data shown in graphs A-II and B-II represent the mean value and the
s (graphs I and II) was below 12.7%.).
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pled rat liver mitochondria. In all experiments, the mitochon-
dria were pre-incubated with the drug for 5 min. This time
period is sufficient to give the maximum inhibitory effect for
all substrates [12], before initiation of state 3 oxidation. The
addition of ADP was delayed for the same period of time
in the controls. The absolute reference values for the
oxidation rates, expressed in nmol O2/min/mg protein,
were: 52.1, 40.9, 42.8, and 20.4 respectively for succinate
(plus rotenone), L-glutamate (plus L-malate), L-glutamate and
2-oxoglutarate.
In agreement with the results obtained when ATP synthesis
was studied, VPA inhibited glutamate and 2-oxoglutarate
oxidation (state 3) to a similar extent (Fig. 1B-I). The oxygen
consumption with succinate/rotenone was not significantly
affected by VPA and only a very mild effect (20–25%; 1 mM
VPA) was obtained with glutamate/malate as substrate couple.
State 4 oxygen consumption remained practically unchanged
with all substrates as compared to control values, except for
glutamate where a slight increase was found. In accordance with
the ATP results, Fig. 1B-II shows that Δ4-VPA (at 1 mM)
inhibited the oxidation of the same substrates to a similar extent
as VPA (1 mM).Fig. 2. Linearization plots of dihydrolipoamide dehydrogenase (DLDH) activity in the
dephosphoCoA (graphs A-II and B-II): graph A (I and II)—Lineweaver–Burk plot2.3. Effect of valproyl-CoA and valproyl-dephosphoCoA on the
enzyme activity of E3 subunit
The dihydrolipoamide dehydrogenase activity (E3) was linear
up 0.1 U/mL. Thus further experiments on substrate dependence
and the effect of inhibitors on the E3 activity were performed
using a protein concentration of 0.05 U/mL. The effect of
increasing concentration of NADH (0–400 μM) on E3 activity
was also studied, providing an estimated Km of 37.3 μM and a
Vmax of 2.5 μmol/min/mg respectively. Further experiments
were performed using a fixed concentration of 150 μM of
NADH, thus ensuring that NADH would not be limiting flux
through the enzyme. The activity of E3 as a function of
increasing concentration of lipoamide (0.25–3.0 mM) was
determined. The kinetic constants Km and Vmax were estimated
by the linearizations of the Michaelis–Menten equation and by
the fit of this equation to the experimental data points using the
non-linear regression software. A Km of 0.49 mM and a Vmax of
1.0 μmol/min/mg were respectively obtained.
The activity of DLDH was determined in the presence of the
potential inhibitors valproyl-CoA (0.5 and 1.0 mM) and
valproyl-dephCoA (0.5 and 1.0 mM) at various lipoamide
concentrations. Fig. 2 displays the kinetic data of E3 activitypresence of valproyl-CoA (graphs A-I and B-I) and in the presence of valproyl-
(1/V= f (1/[S])) graph B (I and II)—Eadie–Hofstee plot (V= f(V/[S])).
Fig. 3. Measurement of dihydrolipoamide dehydrogenase activity as a function
of substrate (lipoamide) concentration (0.25 to 3.0 mM) in the absence and in the
presence of valproyl-CoA (A) and valproyl-dephCoA (B). The dashed lines
represent the curve simulations based on the estimated kinetic parameters
obtained with the inhibitors, superimposed to our experimental data, in parallel
to the best-fits obtained in the absence of inhibitor (upper curves) (see Materials
and methods and Results for experimental conditions and data analysis).
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the linearization procedures of Lineweaver–Burk (Fig. 2 AI and
AII) and Eadie–Hofstee (Fig. 2 BI and BII). The Hanes–Woolf
linearization and the direct linear plot of Cornish Bowden were
also used to analyse the experimental data (plots not shown).
The results clearly show an inhibition of DLDH activity
induced by valproyl-CoA (Fig. 2 AI and B-I) and valproyl-
dephCoA (Fig. 2 A-II and B-II) at physiological concentrations.
On the basis of the overall graphical analysis, our data suggest a
clear distinction between the mechanisms of inhibition assigned
to the two tested compounds: valproyl-CoA seems to interact as
a pure competitive inhibitor and valproyl-dephCoA appears to
be an uncompetitive inhibitor.
The kinetic parameters (Vmax′ and Km′, expressed in μmol/min/
mg and mM respectively) for each inhibitor were calculated
according to the different linearization procedures. The following
average values were obtained: valproyl-CoA, 0.5 mM (Vmax′ =
1.01 and Km′=0.63) and 1.0 mM (Vmax′ =0.85 and Km′=0.61),
valproyl-dephCoA, 0.5 mM (Vmax′ =0.69 and Km′=0.29) and
1.0 mM (Vmax′ =0.54 and Km′=0.17). To further confirm the







and V Vmax=Vmaxð Þ= K Vm=Kmð Þ which are bilinear
functions of the inhibitor concentration [I] [25].The graphic representation of our data according to these
functions was in accordance with the assumption that valproyl-
CoA and valproyl-dephCoA inhibit E3 activity by the two
presumed models of inhibition (data not shown). Therefore, the
respective values of KI were calculated for valproyl-CoA and
valproyl-dephCoA following the respective inhibition models.
A KI of 1.60 mM for valproyl-dephCoA was calcu-
lated through the graphic representation of the ratio
K Vm
Km




, where KI is the obtained re-
ciprocal of the slope. For valproyl-CoA, the KI obtained by the
bilinear function was further confirmed with another graphic
representation (method of Dixon) [26] given by 1/V= f([I]) and
a value of 1.43±0.29 mM was obtained.
Using the kinetic parameters calculated as described above
(valproyl-CoA: KI = 1.43 mM and valproyl-dephCoA:
KI =1.60 mM) the hyperbolic curves of DLDH activity versus
[S] in the presence of both inhibitors were simulated for the
various values of Km′ and Vmax′ . Fig. 3 represents the curve
simulations obtained with the inhibitors superimposed to our
experimental data, in parallel to the best-fits obtained in the
absence of inhibitor. As shown in Fig. 3A, in the presence of
0.5 mM and 1.0 mM of valproyl-CoA, the apparent Km tends to
increase and Vmax is not significantly affected, as expected for a
competitive inhibitor. However, as shown in Fig. 3B, valproyl-
dephCoA at 0.5 and 1.0 mM inhibits E3 activity by an
uncompetitive mechanism, affecting both the values of Km that
increases and Vmax that decreases.
3. Discussion
Valproate and its unsaturated metaboliteΔ4-VPAwere found
to be clear inhibitors of 2-oxoglutarate- and glutamate-driven
oxidative phosphorylation and of the respiration rate sustained
by these substrates. Interestingly, no inhibitory effect was found
on respiration and ATP synthesis when succinate, in the
presence of rotenone, and glutamate, in the presence of malate,
were used as respiratory substrates.
The present data on the effect of VPA on OXPHOS show that
VPA is not affecting the electron transport chain per se (after
complex II) or strictly the phosphorylation system, as we have
previously reported [13]. In fact, since the ATP production rate
obtained with succinate/rotenone as substrate remained unaf-
fected by valproate, the drug does not affect the synthesis of ATP
from ADP and phosphate. However, the effects induced by VPA
observed in the presence of 2-oxoglutarate and glutamate as
single respiratory substrates are clearly indicative of a common
underlying mechanism of inhibition. These substrates share
some common aspects in their metabolism. In hepatocytes,
glutamate is transported from the cytosol into the mitochondria
where it undergoes oxidative deamination catalysed by L-
glutamate dehydrogenase present in the matrix, yielding 2-
oxoglutarate and ammonia. 2-Oxoglutarate can be also imported
into mitochondria directly by a specific carrier in the
mitochondrial membrane and converted via the citric acid
cycle until full oxidation to CO2 and H2O.
Several hypotheses were formulated to explain the obtained
results and to establish the linkage between these substrates.
1131P.B.M. Luís et al. / Biochimica et Biophysica Acta 1767 (2007) 1126–1133The observed inhibitory effects of VPA and Δ4-VPA on
mitochondrial ATP synthesis in the presence of pyruvate, 2-
oxoglutarate and glutamate is likely due to an inhibitory effect on
their respective mitochondrial oxidation and/or on their specific
transport systems embedded in the mitochondrial inner mem-
brane. Since the hypothesis of the defective import into
mitochondria would implicate an effect on at least three different
transport systems (pyruvate carrier, 2-oxoglutarate carrier and
glutamate transport systems), which seemed unlikely, we
reasoned that specific inhibition of dihydrolipoamide dehydro-
genase (E3 subunit) would be the most likely mechanism to
investigate. Fig. 4 depicts the integrated scheme of the metabolic
relationships referred above. As illustrated, an interaction of the
intramitochondrial metabolites of VPA with the E3 subunit
activity would impair the oxidation rates of both 2-oxoglutarate
and glutamate as reported in this work and that of pyruvate as
reported earlier by our group [13]. In order to find evidence for
this, the activity of E3 subunit was studied and characterized in
the presence of valproyl-CoA, the most abundant CoA ester of
VPA in the mitochondrial matrix [15] and in the presence of its
dephosphorylated product [18]. The present work reports a VPA
associated decrease on ATP synthesis rate driven by specific
respiratory substrates and it has been previously reported by our
group that any intramitochondrial depletion on ATP would
increment the conversion rate of valproyl-CoA into valproyl-
dephosphoCoAwith its subsequent concentration increase in the
matrix [18]. Our data suggest that DLDH is apparently one
potential target of toxicity of this metabolite. Thus the results
obtained with the second ester of VPA are of great importance,
since the understanding of the potential toxic significance ofFig. 4. A simplified schematic representation of the inhibitory effect induced by valpr
affecting the oxidative metabolism of 2-oxoglutarate, glutamate and pyruvate as we
pyruvate dehydrogenase complex; 2-OGDH: 2-oxoglutarate dehydrogenase complex
Glut/AspC: glutamate/aspartate carrier; 2-OGC: 2-oxoglutarate carrier).valproyl-dephosphoCoA formation in mitochondria, remains to
be fully elucidated.
Due to the very limited amount of Δ4-VPA, not commer-
cially available, it was not possible to study its direct effect on
E3 activity or to synthesize its CoA ester. Therefore further work
is required to evaluate the potential inhibitory role of Δ4-VPA
or Δ4-VPA-CoA on this enzyme.
Our present results show that valproyl-CoA and valproyl-
dephCoA formed intramitochondrially after activation of VPA,
both inhibit the activity of DLDH. Being the common com-
ponent (E3) of the multienzyme complexes pyruvate dehydro-
genase and 2-oxoglutarate dehydrogenase (as well as branched
chain 2-oxoacid dehydrogenase) we may predict that these
mitochondrial enzymes will also be affected by VPA and/or
valproyl-CoA (or -dephCoA). The subsequent reduced rate of
NADH and possibly FADH2 production in the mitochondrial
matrix may explain the reported decrease of oxygen consump-
tion induced byVPA, in the presence of the substrates mentioned
above.
Kinetic analysis suggests that valproyl-CoA inhibits DLDH
by a purely competitive mechanism whereas valproyl-dephCoA
interacts with the enzyme by a purely uncompetitive mecha-
nism. A deeper insight into the binding mode of these acyl
thioesters related with enzyme structural data needs further
investigation in order to shed some light to this differential
mode of inhibition.
In agreement with our findings, a competitive inhibition of
beef brain 2-OGDHC by valproyl-CoA and Δ2,3-valproyl-CoA
(1 mM) was reported earlier by Luder et al. [27]. Moreover,
patients receiving valproate have been reported to have higheroyl-CoA and valproyl-dephCoA on mitochondrial dihydrolipoyl dehydrogenase,
ll as the catabolism of glycine. (Abbreviations of enzymes and carriers: PDH:
; GCS: glycine cleavage system; DC: dicarboxylate carrier; PC: pyruvate carrier;
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the excretion of the deaminated acid metabolites of valine,
isoleucine and leucine [28]. These in vivo effects clearly indicate
an interaction between valproate and branched-chain amino acid
metabolism, where the possible inhibition on BCODHC has to be
considered. Concerning the effect of valproate on PDHC activity,
although it has been evoked as a possible interaction site [13,29],
to our knowledge however, no direct evidence showing the in-
terference of VPA with this enzyme has been reported.
Although rarely mentioned, DLDH also participates in the
glycine cleavage system (GCS) by reoxidising the dihydroli-
poyl moiety of the hydrogen carrier protein of the system, which
is required for the metabolism of glycine to N5, N10-methylene-
tetrahydrofolate, CO2 and NH4
+ [14]. Interactions of VPA with
the GCS have also been demonstrated in the literature [16,17],
but none of those reports have assigned the inhibitory effects of
VPA on GCS with a potential VPA-induced decrease in DLDH
activity. Moreover, our results may partly explain the reported
effects of VPA on the mitochondrial glycine cleavage system
and the hyperglycinemia associated with VPA treatment. This
phenomenon has remained unexplained so far.
It is interesting to verify the clinical and biochemical
spectrum of abnormalities that may eventually exist between a
genetic and an acquired (drug-induced) deficiency in the E3
subunit. Inherited defects in lipoamide dehydrogenase are rather
rare disorders in humans and the impairment of the enzyme is
much more striking than the mild in vitro effect that we report in
this work. The clinical presentation and course is variable,
ranging from acidemia in early childhood, infantile neurode-
generative disease and death in many cases. But interestingly,
hepatic impairment has occurred in a case of a genetic defect of
E3 [30] and a clinical picture with Reye-like liver involvement
without mental retardation has also been described in the
Ashkenazi-Jewish population [31,32]. A mild DLDH deficien-
cy has been reported in an adult case only with hepatocellular
injury and without central nervous system involvement [33]. In
fact, a benign or severe form of liver dysfunction has been
documented in many cases of valproate associated hepatotox-
icity [34].
Furthermore, studies with three cell lines (fibroblasts) of
DLDH deficient patients showed that ATP production rates
were decreased in all of them, suggesting in addition that there
is an ATP synthesis threshold below which serious neurological
disease becomes evident [35]. According to the authors, a slight
increment of ATP synthesis rate was likely sufficient for
moderate brain protection. Transposing these considerations to
our results, we would like to find the answer to one immediate
question: what would the critical ATP synthesis threshold be for
liver disease and hepatotoxicity? Considering that ATP is at the
crossroad of the major metabolic pathways, our present findings
may have interesting implications in cell toxicity associated
with VPA therapy.
Although other mechanism(s) may account for the notorious
effect on 2-oxoacids-driven OXPHOS and respiration rates
observed in vitro in the presence of VPA, these reported effects
may well be explained, at least in part, by the inhibition of
DLDH by the CoA (or dephCoA) esters of the parent drug.Acknowledgments
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